Assessment of Tumor Marker CA15-3,Estrogen and Progesterone Hormones and Detection of Genes Mutation in Patients with Breast Cancer

Abstract

In these Study of 100 Patients with Breast Cancer from Radiation and Isotopes Cancer in Khartoum (RICK) and 50 Apparently apparently . healthy individuals as controls during the petiod march to December 2011 we have prospectively assessed the role of CA15-3 estrogen and progesterone hormones as a marker of hreast of breast cancer . The cancer associated antigen CA15-3 was detected in serum and is widely used as a patients with breast cancer before chemotherapy and then the level of CA15-3 was measured every three months after 3 months, 9 months . these fallow – up of Ca15-3 has clinical important because CA15-3 is the most sensitive test in detecting metastatic breast cancer . the intensive postoperative fallow – up has been shown to be useful only diagnosis but not in improving clinical outcome . in these tials clinical instrumental was compared with clinical only fallow – up and neither any serum tumor marker panel nor appropriate criteria for its use were adopted the level of CA15-3 showed significant difference when the study group was compared with the control group (p<0.005 ) mean +SD for control versus patients (59.7+3.40 )The level of CA15-3 in postoperative patients showed no significant difference compare to the mean of CA15-3 after three months from chemotherapy (p<0.005 ) Mean +SD for CA15-3 versus three months after chemotherapy ( 59.7+4.6 versus 56.4+4.8 SUL ) The level of CA15-3 after three months of chemotherapy showed no significant difference compared to the mean of months of chemotherapy showed no significant difference compared to the mean of the level after six months ( p>0.005 ) Mean + SD for six months after chemotherapy versus nine months of chemotherapy ( 66.8+6.0 versus 93.4+9.8 ) The serum levels of estrogen hormone were significantly differently difference in with breast cancer group and the control group ( mean + S.D: 306+130 versus 111+65 pg/ml; p<0.001 ) Results for serum progesterone showed significant difference between patients and control ( mean+S.D: 31.5+12.6 versus 14.6+6.9 pg/ml , p<0.001 ) . In this study the patients whose ages over 50 years were have breast cancer disease (72% ) more than the patients whose ages less than 50 years (28% ) There was positive association between family history of disease accounted (63% ) . There was a relationship between the degree family history of disease and breast cancer the first degree of family history disease accounted 66% of the patients who had family history disease .In this study there were significant difference between the mean of BMI in patients wich breast cancer and control group ( mean + S.D: 32.2+7.7 versus 22.8+3.4 kg/m2 p<0.001 ) 33 ( 33%)of patients with breast cancer were identified as having a previous history of oral contraceptive usage and 67 (67% ) of patients cancer were not use oral contraceptive there was no association breast cancer disease and benign breast disease 16 ( 16% ) of patients with breast cancer were identified as having a past history of benign breast disease there were no association between breast cancer disease and other chronic disease , diabetes (33%) hypertensive (32 % ) thyrodisim (21%) there were association of breast cancer disease and the tribe of the patients . The northern tribes are the most freguent tribes in the center of sudan . Gaal yaeen tribes represented 43(43%) of the study subjects . This study was conducted to estimate the frequency of BRCA1and BRCA2 gene mutations in Sudanese female patients with breast cancer . BRCA1 and BRCA2 genes were determined using specific primers and multiplied by PCR . The mutations of the 2 genes were detected on 2 exons ( 8 and 13 ) on Brca 1 and exon 9 on BRCA 1 using single strand conformation polymorphism (SSCP) assay . The results show no obvious mutation detected on both genes as indicated by silver polyacrylamide gel electrophoresis